



VoxCell BioInnovation

APRIL 11, 2022

FOR IMMEDIATE RELEASE

VOXCELL HAS FINALIZED FIRST CLOSING OF PRE-SEED ROUND AND WILL BE SHOWCASED IN MULTIPLE EVENTS

Victoria, BC – Recent and Upcoming Events:

VoxCell pitched at the [Angel Forum](#) event on Friday, April 8th. The event showcased many BC Start-ups and brought together an incredible group of Angel Investors.

During this month, VoxCell will be also pitching at the [IME WEST](#) on April 13th, at the MD&M division (Medical Devices & Manufacturing), where 13,000 attendees are expected! Following IME WEST, VoxCell will be giving a pitch and a poster at the [Life Sciences Innovation Northwest](#) on April 20th.

These events are coming at a great time for VoxCell since we are currently fundraising. VoxCell's pre-seed round of \$1M USD (equity round) opened in December 2021, and we did our first closing of \$550K USD in March ([Lead Investor: eFund](#)). Our second closing will be in May 2022, and we are looking for \$450K USD.

The funds will be used to fund our validation studies, in which drug efficacy in our human-like cancer tissue models will be compared with animal models; to file provisionals on our tissue models and new bioinks; and begin sales of our bioink and tissue models by the end of 2022.

About VoxCell BioInnovation

VoxCell™ is a biotechnology start-up on the west coast of Canada focused on providing an extraordinary line of solutions for the drug development industry and the field of Oncology research by creating Human-Like vascularized cancer tissue models.

VoxCell's mission is to impact the world by reducing the time and cost required to take an anti-cancer to the market, with the potential to reduce the number of animal tests performed on the drug development process.

MEDIA CONTACT:

Dr. Karolina Valente
CEO & CSO, kvalente@voxcellbio.com